Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
  2. Allergan assesses brazikumab in two clinical programmes for IBD
  3. AstraZeneca reports negative top-line results from TULIP 1 trial
  4. Arrowhead concludes dosing in Phase I ARO-AAT trial
  5. Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market

Latest Content

Bristol-Myers Squibb’s drug trial fails to meet primary endpoint

Bristol-Myers Squibb has reported that the Phase III CheckMate -451 study failed to meet its primary endpoint of overall survival (OS) with opdivo (nivolumab) as a maintenance therapy in patients with extensive-stage small cell lung cancer (SCLC) after completion of first-line chemotherapy.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top